Core Viewpoint - A lawsuit has been filed against Reddit, Inc. and its senior executives for potential violations of federal securities laws, specifically related to misrepresentations about user growth impacted by Google's AI technology [1][2][3]. Company Overview - Reddit operates a social news aggregation and forum platform, which has seen a decline in user traffic due to Google's AI search results providing answers directly, reducing the need for users to visit Reddit [3][4]. Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Northern District of California, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. Stock Performance - Following a report on May 1, 2025, indicating a slowdown in daily active user growth, Reddit's stock price fell from $118.79 to $113.83, a decline of $4.96 or over 4% [5]. - On May 21, 2025, after an analyst cut the stock price target due to concerns over Google's AI impact, Reddit's stock dropped from $105.64 to $95.85, a decrease of $9.79 or over 9% [6].

Core Viewpoint - A lawsuit has been filed against Organon & Co. and certain senior executives for potential violations of federal securities laws, particularly related to misleading statements about the company's dividend policy following a significant acquisition [1][2]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of New Jersey, titled Hauser v. Organon & Co., et al., No. 25-cv-05322, and claims are made under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [2]. - Investors have until July 22, 2025, to request to be appointed to lead the case [2]. Group 2: Company Background and Acquisition - Organon is a global healthcare company focused on women's health, known for rewarding shareholders with dividends [3]. - In October 2024, Organon completed a $1.2 billion acquisition of Dermavant, a biopharmaceutical company, which increased its debt [3]. Group 3: Dividend Policy and Stock Performance - Following the acquisition, Organon assured investors it would maintain its dividend, which was stated as its "1 capital allocation priority," but later shifted focus to debt reduction, leading to a significant cut in dividends [3]. - On May 1, 2025, Organon announced a reduction in its dividend payout from $0.28 per share to $0.02 per share, resulting in a stock price decline of approximately 27%, from $12.93 to $9.45 per share [4].

Core Viewpoint - A lawsuit has been filed against Hims & Hers Health, Inc. and its senior executives for potential violations of federal securities laws, following allegations of misrepresentation regarding a partnership with Novo Nordisk [1][2][4]. Group 1: Lawsuit Details - Investors have until August 25, 2025, to request to lead the case, which is pending in the U.S. District Court for the Northern District of California [2]. - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities [2]. - Two complaints have been filed, with the first case titled Sookdeo v. Hims & Hers Health, Inc., and a subsequent similar complaint titled Yaghsizian v. Hims & Hers Health, Inc. [2]. Group 2: Allegations Against Hims & Hers - Hims & Hers operates a telehealth platform providing access to healthcare consultations and wellness products, and recently announced a collaboration with Novo Nordisk to sell the weight loss drug Wegovy [3]. - Allegations include misrepresentation of the partnership with Novo Nordisk, specifically regarding the sale of Wegovy and compounded semaglutide, and claims of compliance with FDA regulations [4]. Group 3: Stock Impact - Following Novo Nordisk's announcement of terminating the partnership due to Hims & Hers' alleged deceptive practices, Hims & Hers' stock price fell by $22.24 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.98 on June 23, 2025 [5].

Core Point - The Supervisory Board of Admirals Group AS has decided to recall Mr. Lauri Reinberg from the Management Board effective 26 June 2025 [1] Group 1 - Mr. Reinberg's authorizations will terminate on 25 June 2025 [1] - The Management Board will continue with members Alexander Tsikhilov, Eduard Kelvet, Anton Tikhomirov, and Andrey Koks effective 26 June 2025 [1] - Alexander Tsikhilov is the Chairman of the Management Board [1]

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc. Investors have until July 11, 2025, to ask the Court to be appointed t ...

NEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Fortrea Holdings Inc. (NASDAQ: FTRE) and certain of the Company’s senior executives for potential violations of the federal securities laws. If you invested in Fortrea you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/fortrea-holdings-inc-class-action-lawsuit. Investors have until August 1, 2025, to ask th ...

香港交易及結算所有限公司及香港聯合交易所有限公司（「聯交所」）對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部份內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Shanyu Group Holdings Company Limited ⑂垓斄◖㉥佟㗇攎⊶ （於開曼群島註冊成立的有限公司） （股份代號：8245） 截至二零二五年三月三十一日止年度之年度業績 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他在 聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等公 司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買 賣之證券承受更大的市場波動風險，同時無法保證在GEM買賣的證券會有高 流通量的市場。 本公告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨 在提供有關善裕集團控股有限公司（「本公司」）的資料；本公司的董事（「董事」， 各自為一名「董事」）願就本公告的資料共同及個別地 ...

截至二零二五年三月三十一日止年度 業績公佈 | 財務摘要 | | | | | | --- | --- | --- | --- | --- | | （除另有註明外，金額以百萬港元列示 | | | | | | | 二零二五年 | 二零二四年 | | 變動 | | 物業合約銷售 | | | | | | －附屬公司 | 3,214 | 1,451 | | | | －合營企業（集團分佔） | 304 | 387 | | | | | 3,518 | 1,838 | | +91% | | 收入 | 2,509 | 1,903 | | +32% | | 本公司股東應佔虧損 | (2,235)) | (3,769 | ) | -41% | | 每股虧損－基本（港元） | (2.66)) | (4.48 | ) | -41% | | 資產總值 | 34,638 | 38,212 | | -9% | | 資產淨值 | 14,885 | 18,118 | | -18% | | 本公司股東應佔權益 | 7,765 | 9,507 | | -18% | | 債務淨額 | 14,229 | 16,363 | | -13% | | 酒店物業 ...

Core Viewpoint - The article emphasizes the "dual importance" of ESG disclosures, highlighting the need for companies to enhance their climate-related information reporting to meet regulatory expectations and stakeholder demands [1][2]. Policy Updates - The Ministry of Finance has released an ESG disclosure application guide, reinforcing the dual importance and value chain disclosures [2]. - New standards for addressing climate change have been introduced, presenting companies with challenges in carbon accounting, reduction, and adaptation [2]. - The National Energy Administration reports that renewable energy installations have surpassed 2 billion kilowatts, with wind and solar power exceeding thermal power for the first time [2]. Industry Insights - 22 ESG-focused securities firms have submitted their ESG reports, but the challenge of climate information disclosure is just beginning [3]. - The Ministry of Ecology and Environment has completed the third marine pollution baseline survey, providing insights into marine ecological health [3]. - A comprehensive carbon footprint management system is being established, with over 70 national standards for product carbon footprint accounting expected to be published by the end of 2024 [3]. Corporate Actions - Yili Group is leading the dairy industry in carbon reduction efforts, collaborating with the entire supply chain to achieve sustainability goals [6][7]. - The company has launched a carbon management platform and has seen significant participation in its "Zero Carbon Alliance," with 90% of members achieving low-carbon transitions [7]. - Yili's ESG report has received the highest rating from the Chinese Academy of Social Sciences, and the company has been recognized as a "chain leader" by the UN Global Compact [7].

Core Viewpoint - New World Development has successfully secured refinancing for approximately HKD 88.2 billion of its existing unsecured offshore financial debt, which will aid in managing ongoing business and financial needs [1][3]. Group 1: Refinancing Details - The new bank financing includes multiple loans with varying maturities, the earliest of which is due on June 30, 2028 [1]. - The refinancing plan is one of the largest in Hong Kong's history, with a total of HKD 87.5 billion (approximately USD 11.1 billion) approved by all banks involved [3]. - If 100% approval is not obtained by June 30, the transaction may collapse, releasing any pledged assets and canceling bank commitments [3]. Group 2: Financial Performance - New World Development reported a revenue of HKD 16.79 billion, a year-on-year decrease of 1.6%, and a core operating profit of HKD 4.416 billion, with a shareholder loss of HKD 6.633 billion [4]. - The company plans to continue selling non-core assets in the second half of the 2025 fiscal year to improve cash flow, with K11 Art Mall listed for potential sale at HKD 9 billion [4]. Group 3: Debt Situation - New World Development has a total borrowing exceeding HKD 151 billion, with a net debt ratio of 57.5%, and short-term debt exceeding HKD 32 billion, while holding only HKD 21.8 billion in cash [6][7]. - The company has faced liquidity challenges due to high leverage and market conditions, prompting management changes and strategic adjustments [6][7].